CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) granted new equity awards this month to three recently hired non-executive employees, signaling continued growth as the company advances its commercial and clinical programs for its breakthrough MASH therapy.
The awards, issued Nov. 15 under Madrigal’s 2025 Inducement Plan and approved by the board’s independent compensation committee, were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The hires received a combined 2,125 time-based restricted stock units, which vest in four equal installments on each of the first four anniversaries of the grant date. Vesting requires continued employment through each milestone.
The inducement awards are designed to attract and retain talent as the company accelerates development of Rezdiffra (resmetirom), its once-daily, liver-directed THR-β agonist and the first therapy approved in both the United States and Europe for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced fibrosis.
Madrigal continues to expand its workforce as it supports the commercial rollout of Rezdiffra and conducts a Phase 3 outcomes trial evaluating the medication in patients with compensated MASH cirrhosis (F4c), a population with few available treatment options.
The company said the new hires reflect ongoing investment in personnel needed to meet the growing demand for novel MASH therapies and advance its broader clinical strategy.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.